Search

Pomalidomide prolongs survival in refractory myeloma patients

Jun 14 2013

MM-003 is a large, multi-centre phase 3 study that assessed the efficacy and safety of a new drug, Pomalidomide (POM) in combination with low-dose dexamethasone (POM+LoDex) and compared this combination with high dose dexamethasone in MM patients with late stage…

Selected EMA news

September 2024Safety update
Withdrawal of Oxbryta (Voxelotor) – marketing authorisation suspended
Treatment of haemolytic anaemia (excessive breakdown of red blood cells) due to sickle cell disease
New medicines approved
Adzynma (rADAMTS13) - orphan medicine
Treatment of congenital thrombotic thrombocytopenic purpura (an inherited clotting disorder)
Other…

EU funding calls for hematology

Horizon Europe
MSCA Feedback to Policy 2024 (deadline: September 4, 2024)
MSCA International Cooperation 2024 (deadline: September 4, 2024)
MSCA Postdoctoral Fellowship 2024 (deadline: September 11, 2024)
Improving the understanding and management of late-effects in adolescents and young adults (AYA) with cancer (deadline: September…

Stopping tyrosine kinase inhibitors in a very large cohort of European chronic myeloid leukemia patients: results of the EURO-SKI trial

Jun 10 2016 Posted in Press releases

Tyrosine kinase inhibitors (TKI) have substantially improved survival in patients with chronic myeloid leukemia in chronic phase. However, treatment is in clinical practice considered life-long.

Hematology in the spotlight at EAPM Presidency Conference

Apr 09 2019 Posted in Press releases

April 9, Brussels - The European Alliance for Personalised Medicine is holding its 7th annual presidency conference at the University Foundation in Brussels, and the event will include a session on Hematology - Personalised treatment and personalised prevention.

Highlights of Past EHA (HOPE) Latin America 2021

For the third edition of the Highlights of Past EHA (HOPE) Latin America (LA), EHA will organize a truly regional meeting by collaborating simultaneously with our hematology partners from the region.

Highlights from the SWG

SWG session at EHA2023The EHA2023 Congress was held in Frankfurt, Germany, in June 2023. As part of this event, the SWG held a session on Saturday, June 10, 2023. Title‘Stem cells: Clonal and mutational dynamics of hematopoietic stem cells.

Hematology Tutorial in Sri Lanka updates expertise on myeloid malignancies and MDS of local hematologists

Apr 17 2019 Posted in Tutorial reports

After a successful first edition in 2017, EHA and the Sri Lanka College of Haematologists (SLCH) organized its second two-day tutorial together in February in Colombo. The tutorial aimed to update the expertise of local hematologists from all levels.

EHA-SLCH Hematology Tutorial on Myeloid Malignancies and MDS

Dates: February 8-9, 2019
Location: Colombo, Sri Lanka
Chairs: G Ossenkoppele, V Gunawardena, HW Goonasekera

After a successful first edition in 2017, EHA is organizing the second two-day tutorial in close collaboration with the Sri Lanka College of Haematologists (SLCH) on "Myeloid malignancies and MDS".…

The 3rd EHA-ISHBT Hematology Tutorial on Lymphoproliferative and Plasma Cell Disorders

May 15 2018 Tagged EHA tutorial, plasma cell disorders, lymphoproliferative and plasma cell disorders

The 3rd EHA-ISHBT Hematology Tutorial on Lymphoproliferative and Plasma Cell Disorders was held on February 16-18 in Lucknow, India, and chaired by Dr AK Tripathi (King George’s Medical University, Lucknow, India) and Prof G Gaidano (University of Eastern Piedmont, Novara,…